Klein B, Brailly H
Institute for Molecular Genetics, CNRS, Montpellier, France.
Immunol Today. 1995 May;16(5):216-20. doi: 10.1016/0167-5699(95)80161-8.
Cytokine-binding proteins (CBPs) block the ability of cytokines to interact with their receptors. These agents can potentially provide a means of treating pathological conditions that have a significant cytokine involvement. However, a major drawback of such approaches relates to the fact that CBPs stabilize the cytokine in the form of a cytokine-CBP complex in vivo. Here, Bernard Klein and Hervé Brailly discuss the possibility that CBPs behave either as agonists or antagonists according to their pharmacokinetic characteristics in vivo, and suggest a mechanism by which stable complexes might be cleared from the system.
细胞因子结合蛋白（CBPs）可阻断细胞因子与受体相互作用的能力。这些药物有可能提供一种治疗与细胞因子显著相关的病理状况的方法。然而，此类方法的一个主要缺点在于，在体内CBPs会以细胞因子 - CBP复合物的形式使细胞因子稳定下来。在此，伯纳德·克莱因和埃尔韦·布莱利探讨了CBPs根据其体内药代动力学特性表现为激动剂或拮抗剂的可能性，并提出了一种可从系统中清除稳定复合物的机制。
